Cargando…

COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications

Detalles Bibliográficos
Autores principales:	Barchetta, Ilaria, Cavallo, Maria Gisella, Baroni, Marco Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177127/ https://www.ncbi.nlm.nih.gov/pubmed/32333966 http://dx.doi.org/10.1016/j.diabres.2020.108165

Ejemplares similares

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
por: Barchetta, Ilaria, et al.
Publicado: (2022)

New Insights in the Control of Fat Homeostasis: The Role of Neurotensin
por: Barchetta, Ilaria, et al.
Publicado: (2022)

High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up
por: Cimini, Flavia Agata, et al.
Publicado: (2021)

Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes
por: Barchetta, Ilaria, et al.
Publicado: (2011)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Hypovitaminosis D is Independently Associated with Metabolic Syndrome in Obese Patients
por: Barchetta, Ilaria, et al.
Publicado: (2013)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease
por: Cimini, Flavia Agata, et al.
Publicado: (2019)

Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future
por: Barchetta, Ilaria, et al.
Publicado: (2017)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Reduced High-Density Lipoprotein Cholesterol Is an Independent Determinant of Altered Bone Quality in Women with Type 2 Diabetes
por: Dule, Sara, et al.
Publicado: (2023)

Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease
por: Cimini, Flavia A, et al.
Publicado: (2017)

Altered Glucose Homeostasis Is Associated with Increased Serum Apelin Levels in Type 2 Diabetes Mellitus
por: Cavallo, Maria Gisella, et al.
Publicado: (2012)

Reply to letter to the editor regarding “Use of DPP-4 inhibitors in patients with COVID-19”
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V
por: Bertoccini, Laura, et al.
Publicado: (2017)

Neurotensin Gene rs2234762 C>G Variant Associates with Reduced Circulating Pro-NT Levels and Predicts Lower Insulin Resistance in Overweight/Obese Children
por: Sentinelli, Federica, et al.
Publicado: (2023)

Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis
por: Velotti, Francesca, et al.
Publicado: (2020)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes
por: Barchetta, Ilaria, et al.
Publicado: (2017)

Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans
por: Bailetti, Diego, et al.
Publicado: (2022)

Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors
por: Yanagawa, Tatsuo
Publicado: (2018)

Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update
por: Cimini, Flavia Agata, et al.
Publicado: (2022)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
por: Gul, Owais, et al.
Publicado: (2019)

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Triiodothyronine prevents tissue hypoxia in experimental sepsis: potential therapeutic implications
por: Mourouzis, Iordanis S., et al.
Publicado: (2021)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
por: Mikhail, Nasser
Publicado: (2008)

Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity
por: Cimini, Flavia Agata, et al.
Publicado: (2020)

No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
por: Barchetta, Ilaria, et al.
Publicado: (2016)

An agonist of the CXCR4 receptor is therapeutic for the neuroparalysis induced by Bungarus snakes envenoming
por: Stazi, Marco, et al.
Publicado: (2022)

Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J 2014;38:211-9)
por: Lee, Seung-Hwan
Publicado: (2014)

Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity
por: Ceccarelli, Valentina, et al.
Publicado: (2020)

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
por: Valencia, Inés, et al.
Publicado: (2020)

A Molecular Modeling Investigation of the Therapeutic Potential of Marine Compounds as DPP-4 Inhibitors
por: Antony, Priya, et al.
Publicado: (2022)

Landscape Profiling Analysis of DPP4 in Malignancies: Therapeutic Implication for Tumor Patients With Coronavirus Disease 2019
por: Shu, Lingling, et al.
Publicado: (2021)

Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID‐19
por: Ghasemnejad-Berenji, Morteza, et al.
Publicado: (2020)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19
por: Firneisz, Gábor
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vdettlo1er6purfu88pmq3sosl